| Bioactive metabolites: a clue to the link between MASLD and CKD? |
| Wen-Ying Chen1, Jia-Hui Zhang2, Li-Li Chen1, Christopher D. Byrne3, Giovanni Targher4,5, Liang Luo6, Yan Ni7, Ming-Hua Zheng1,8,9, Dan-Qin Sun10,11,12 |
1MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
2Department of Paediatrics, The Affiliated Wuxi Children's Hospital of Jiangnan University, Wuxi, Jiangsu, China
3Southampton National Institute for Health and Care Research Biomedical Research Centre, University Hospital Southampton and University of Southampton, Southampton General Hospital, Southampton, UK
4Department of Medicine, University of Verona, Verona, Italy
5Metabolic Diseases Research Unit, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella, Italy
6Intensive Care Medicine, Jiangnan University Medical Center, Wuxi, China
7Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China
8Institute of Hepatology, Wenzhou Medical University, Wenzhou, China
9Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China
10Urologic Nephrology Center, Jiangnan University Medical Center, Wuxi, China
11Affiliated Wuxi Clinical College of Nantong University, Wuxi, China
12Department of Nephrology, Wuxi No.2 People's Hospital, Wuxi, China |
|
|
|
Received: September 9, 2024 Revised: October 15, 2024 Accepted: October 18, 2024 |
|
|
| ABSTRACT |
|
|
Metabolites produced as intermediaries or end-products of microbial metabolism provide crucial signals for health and diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD). These metabolites include products of the bacterial metabolism of dietary substrates, modification of host molecules [such as bile acids (BAs), trimethylamine-N-oxide, and short-chain fatty acids], or products directly derived from bacteria. Recent studies have provided new insights into the association between MASLD and the risk of developing chronic kidney disease (CKD). Furthermore, alterations in microbiota composition and metabolite profiles, notably altered BAs, have been described in studies investigating the association between MASLD and the risk of CKD. This narrative review discusses alterations of specific classes of metabolites, BAs, fructose, vitamin D, and microbiota composition that may be implicated in the link between MASLD and CKD. |
| KeyWords:
metabolic dysfunction-associated steatotic liver disease; chronic kidney disease; metabolites; bioactive metabolites; bile acids; gut microbiota |
|
|
PDF Links
Full text via DOI
Download Citation
